Research programme: cardiac disease - Larnax
Alternative Names: Cardiac disease research programme - LarnaxLatest Information Update: 20 Jul 2004
At a glance
- Originator Larnax (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 31 Dec 2003 Discontinued - Preclinical for Cardiovascular disorders in Germany (unspecified route)
- 01 Apr 2003 MediGene's cardiac and metabolic disease programme has been spun off as a new company, Larnax GmbH
- 21 Oct 2002 MediGene and Evotec OAI, as GENOVATION, have entered into an agreement to codevelop this programme